基于的凝用于纳米系统封装:下一代局部化输送系统用于治疗肠道炎症
Valentina Andretto1, Annalisa Rosso1, Serena Zilio1,2
1Univ Lyon, Université Claude Bernard Lyon 1, CNRS, LAGEPP UMR 5007, 43 Boulevard du 11 Novembre 1918, Villeurbanne, F-69622, France.
Advanced healthcare materials
|March 6, 2024
概括
这项研究开发了一种新的水凝纳米粒子系统,用于治疗炎症性肠道疾病 (IBD). 该系统增强了向炎症肠道的药物输送,改善治疗结果并减少副作用.
科学领域:
- 生物材料科学 生物材料科学
- 胃肠病学 胃肠病学
- 纳米技术 纳米技术
背景情况:
- 传统的炎症性肠病 (IBD) 治疗依赖于全身疗法,往往导致显著的副作用和毒性.
- 纳米粒子为向向炎症组织的药物输送提供了一个有希望的替代方案,最大限度地减少全身暴露.
- 增加纳米颗粒在炎症肠道中的停留时间对于提高治疗疗效至关重要.
研究的目的:
- 开发一种混合脂质聚合物纳米复合体系统,以改善IBD的口服药物输送.
- 研究嵌入粘膜透纳米乳液在基于的水凝矩阵中的潜力.
- 在肠道炎症模型中评估新型纳米复合物的生物分布,物理性质和治疗疗效.
主要方法:
- 混合纳米复合材料的制造,通过将100nm粘膜透纳米乳液集成到一个自组装的基凝 (PuraStat).
- 纳米复合材料的全面表征,包括风学测量和循环二元化分析,以评估微观结构和物理性质.
- 使用小鼠肠炎模型进行体内评估,包括生物分布研究和口服后疾病评分的评估.
主要成果:
- 混合纳米复合材料在胃中表现出仓库的形成,并促进了纳米乳液在肠道中持续释放.
- 鉴定证实了脂质纳米颗粒在水凝结构中的成功整合,而水凝的物理性质没有显著的破坏.
- 药物装载纳米复合物的口服管理显著改善了肠道炎症的小鼠模型中的疾病得分.
结论:
- 开发的基-纳米乳液纳米复合物代表了针对性口服药物输送在炎症性肠道疾病的有希望的战略.
- 这种系统增强了药物在炎症肠道中的停留时间,从而提高了治疗疗效,并减少了全身药物暴露.
- 这些发现表明,有可能开发先进的生物材料,以更有效地管理慢性胃肠道疾病.
相关概念视频
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
332
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
332
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
177
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
177
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
160
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
160
01:26Oral Drug Delivery Systems: Continuous-Release Systems
308
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
308
01:11Oral Drug Delivery Systems: Delayed-Release Systems
222
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
222